NCT00630695

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 148 (actual)
• Sponsor: University Hospital, Limoges · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study

Detailed description

Patients will be recruited among patient refered to our department for a breast cancer and needing an axillary dissection. Enrolled patients will have an injection of Lanreotide or placebo the day before surgery when they arrive in their room. The quantity of lymph in axillary drain will by daily noted until day 4. The patient will be evaluated at D15, D30 and M6 for pain, lymphocele and adverse events. Data will be compared in the 2 groups.

Conditions

• Lymphocele

Interventions

Type	Name	Description
DRUG	Lanreotide LP 90	Lanreotide LP 90
DRUG	Placebo lanreotide	Placebo

Timeline

• Start date: 2008-03-01
• Primary completion: 2011-06-01
• Completion: 2011-12-01
• First posted: 2008-03-07
• Last updated: 2012-01-16

Locations

1 site across 1 country: France